KNRLF yields 3703.70% · PFE yields 6.13%● Live data
📍 KNRLF pulled ahead of the other in Year 1
Combined, KNRLF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of KNRLF + PFE for your $10,000?
Kontrol Technologies Corp., through its subsidiaries, provides energy management, emission compliance, and air quality solutions and services in Canada and the United States. It offers turn-key solutions to building owners and asset managers in the commercial, industrial, and multi-residential sector, which include software to analyze the management of heating, cooling, and ventilation (HVAC) systems; design and engineering of improvements and/or retrofits; and ongoing mission critical services. The company also provides integrated installations of heating, ventilation, cooling, and business automation systems to its customers; greenhouse gas verification, installation of critical emission management systems, and stack testing for environmental emissions; and Kontrol BioCloud, a solution to provide real-time viral detection technology. In addition, it offers energy auditing, monitoring and verification, energy project assessment, mechanical, electrical, and renewable design, as well as LEED facilitation services; monitoring, operation, and service of essential heating, cooling, ventilation, and utility systems; stack emission testing, continuous emission testing, power generation, due diligence, odour assessment and analytics, compliance, and other engineering services; and monitoring solutions, services, and product sales. The company is headquartered in Vaughan, Canada.
Full KNRLF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.